健永生技 MENS 深 沪
已收盘 08-28 16:00:00 美东时间
2.37
+0.070
+3.04%
华盛通- 最 高2.42
- 今 开2.30
- 成交量 2.24万股
- 最 低 2.30
- 昨 收 2.30
- 总市值 1.80亿
- 52周最高 67.00
- 市盈率 静 --
- 换手率 0.03%
- 52周最低 1.43
- 委 比 7.93%
- 总股本 7602.77万
- 历史最高 67.00
- 量 比 1.09
- 振 幅 5.22%
- 历史最低 1.43
- 每 手 1
- 风险率 21.24%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Jyong Biotech Highlights Multi-Billion Dollar Global BPH Market Opportunity and Reaffirms Strategic Focus on Global Licensing Partnerships
Jyong Biotech Ltd. reaffirms its focus on global licensing partnerships to address unmet medical needs in urology, particularly for Benign Prostatic Hyperplasia (BPH). As the first Taiwanese company to advance an oral botanical drug to U.S. FDA Phase III trials, Jyong Biotech is leveraging its botanical drug platform to expand its presence in the global market. With a growing BPH patient population and increasing treatment market size, the compan...
07-23 14:52
Jyong Biotech Showcases Botanical Drug Portfolio at BIO 2026 International Convention
Jyong Biotech Ltd. participated in the BIO International Convention 2026 in San Diego, showcasing its botanical drug candidate, Botreso® (API-1), targeting benign prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTS). The company has conducted four Phase III clinical trials in the U.S. and Taiwan, highlighting the drug's safety and efficacy. With an aging population and rising obesity rates driving market growth, Jyong Biotech aims ...
07-02 12:00
Jyong Biotech CEO Outlines FDA Pathway and Global Strategy in PharmaBoardroom Live Interview
Jyong Biotech Ltd., a biotechnology company, highlights its strategic vision to develop innovative plant-derived therapeutics. CEO Fu-Feng Kuo emphasizes the Company’s hybrid operating model, combining Taiwanese R&D with US regulatory expertise to meet FDA standards. The Company’s proprietary chylomicron and micelle technologies enhance drug bioavailability, with invention patents across the US, EU, and Asia. Its lead asset, Botreso® for benign p...
05-29 12:00
Jyong Biotech Delays Annual 20-F (Yearly Report)
Jyong Biotech Ltd. ( ($MENS) ) has released a notification of late filing. Jyon...
04-30 02:19
Jyong Biotech Advances Market Access Strategies For Its Plant-Based Drugs Botreso And PCP After Analysis Of Their Clinical Efficacy And Competitive Advantages
As previously announced, its first core product, Botreso®, has completed four Phase III clinical trials (API-1) in the United States and Taiwan while its second core product, PCP, has successfully completed its
04-28 20:37
Jyong Biotech Updates the Potential Clinical Benefits and Advantages of Its Plant-Derived Innovative Drug MCS®-2
Jyong Biotech Ltd., a biotechnology company based in Taiwan, has provided updates on MCS-2, an innovative plant-derived drug developed to treat benign prostatic hyperplasia and lower urinary tract symptoms (BPH/LUTS). MCS-2 is the first oral botanical drug globally to complete Phase III clinical trials, with data from trials showing excellent safety and no serious adverse events. The company believes MCS-2 addresses the unmet need for a safe, lon...
03-27 12:30
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers CASI Pharmaceuticals (NASDAQ:CASI) shares rose 54.2% to $0.32 during W...
02-26 05:07
Jyong Biotech Completes Phase II Trial For MCS-8, Expands Commercial Presence In Asia
- Comprehensive review of recent milestones highlights statistically significant efficacy in prostate cancer prevention, discovery of novel lipid-modulating properties, and the execution of high-value commercial
02-12 21:55
